ロード中...
Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor–treated CML stem cells
Treatment of chronic myelogenous leukemia (CML) with BCR-ABL tyrosine kinase inhibitors (TKI) fails to eliminate leukemia stem cells (LSC). Patients remain at risk for relapse, and additional approaches to deplete CML LSC are needed to enhance the possibility of discontinuing TKI treatment. We have...
保存先:
| 出版年: | Blood |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Hematology
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5146743/ https://ncbi.nlm.nih.gov/pubmed/27621307 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-11-679928 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|